

✓
Please insert the following section on Page 1, line 1 of the specification immediately following the Title of the invention---

CROSS-REFERENCE TO RELATED APPLICATIONS

A1
This application is a continuation of application serial no. 09/436,076, filed November 8, 1999, which is a continuation of application serial no. 08/948,393, filed October 10, 1997, now abandoned, which is a continuation of application serial no. 08/377,798, filed January 24, 1995, now abandoned, which is a continuation-in-part of application serial no. 08/253,663, filed May 3, 6/3/94 1994, now abandoned.---

IN THE CLAIMS:

✓
Please cancel claims 1-38 without prejudice.

✓
Please add the following new claims:

39. A method for treating or inhibiting atherosclerosis in a mammal, comprising:
providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin, and between E-selectin and a ligand of E-selectin; and
administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of an inhibitory protein, an inhibitory peptide, an inhibitory carbohydrate, an inhibitory antibody, an inhibitory sulfatide, a substance obtained from a snake venom a plant extract, and an inhibitor of granular release.
40. ✓ The method of claim 39 wherein said agent is administered to the mammal in conjunction with a vessel-corrective technique.

41. The method of claim 40 wherein the vessel corrective technique is selected from the group consisting of angioplasty, a stenting procedure, atherectomy, and bypass surgery.
42. The method of claim 39 wherein said P-selectin is on a cell.
43. The method of claim 39 wherein said cell is an endothelial cell.
44. The method of claim 42 wherein said cell is a platelet.
45. The method of claim 39 wherein said E-selectin is on an endothelial cell.
46. The method of claim 39 wherein said ligand of P-selectin comprises a carbohydrate.
47. The method of claim 39 wherein said ligand of P-selectin comprises a glycoprotein.
48. The method of claim 39 wherein said ligand of P-selectin is selected from the group consisting of sialyl-Lewis x, sialyl-Lewis a, sialyl-Lewis x-pentasaccharide, polyactosaminoglycan, carbohydrate containing 2,6 sialic acid, Lewis x 3'-O-sulfate, heparin oligosaccharides, PSGL-1, 160 kD monospecific P-selectin ligand and lysosomal membrane glycoproteins.
49. The method of claim 39 wherein said ligand of P-selectin is on a cell selected from the group consisting of monocytes, neutrophils, eosinophils, CD4+ T cells, CD8+ T cells, and natural killer cells.
50. The method of claim 39 wherein said ligand of P-selectin is on a leukocyte.
51. The method of claim 50 wherein said leukocyte is a neutrophil.

[illegible]

- Sub B3

- A2

Sub B4
69. A therapeutic agent in a dosage form and concentration suitable for treating or inhibiting atherosclerosis in a mammal in need of such treatment, said agent being effective to inhibit interaction between P-selectin and a ligand of P-selectin or between E-selectin and a ligand of E-selectin, wherein said therapeutic agent is selected from the group consisting of an inhibitory protein, an inhibitory peptide, an inhibitory carbohydrate, an inhibitory antibody, an inhibitory sulfatide, a substance obtained from a snake venom or a plant extract, and an inhibitor of granular release.

AB
70. The method of claim 39, wherein said inhibitory carbohydrate is a heparin oligosaccharide.

Sub B5
71. The method claim 39, wherein said agent is administered at a dose of about 0.01 to about 200 mg/kg body weight.

72. The method of claim 69, wherein said agent is administered at a dose of about 1 to about 100 mg/kg body weight.

73. The method of claim 39, wherein said agent further inhibits interaction between L-selectin and a ligand of L-selectin.

74. A method for treating or inhibiting atherosclerosis in a mammal, comprising:
providing an agent for inhibiting interaction between P-selectin and a ligand of P-selectin and between L-selectin and a ligand of L-selectin; and
administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur.

75. The method of claim 39, wherein said P-selectin ligand is PSGL-1 or a fragment thereof.

Sub B6

A2

80. A method for treating or inhibiting atherosclerosis in a mammal comprising:
providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin; and
administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is a mimetic of an inhibitory carbohydrate of P-selectin or the ligand of P-selectin.

81. A method for treating or preventing restenosis in a mammal, comprising:
providing a method for inhibiting an interaction between P-selectin and a ligand of P-selectin, or between E-selectin and a ligand of E-selectin; and
administering an effective amount of said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of an inhibitory protein, an inhibitory peptide, an inhibitory carbohydrate, an inhibitory antibody, an inhibitory sulfatide, a substance obtained from a snake venom, a plant extract, and an inhibitor of granular release, said agent being administered in conjunction with or after a vessel-corrective technique.

82. The method of claim 81, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

83. The method of claim 81, wherein said agent comprises a soluble form of a P-selectin ligand or a fragment thereof.

84. The method of claim 81, wherein said agent is administered in sequential exposures over a period of hours, days, weeks months or years.

85. The method of claim 81, wherein said agent is administered in combination with other therapeutic agents.

86. The method of claim 81, wherein said P-selectin ligand is PSGL-1 or a fragment thereof.

87. The method of claim 81, wherein said agent is a mimetic of an inhibitory carbohydrate of P-selectin or the ligand of P-selectin.

88. A method for treating or inhibiting atherosclerosis in a mammal comprising:
providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin; and

administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of an inhibitory protein, an inhibitory peptide, an inhibitory carbohydrate, an inhibitory antibody, an inhibitory sulfatide, a substance obtained from a snake venom a plant extract, and an inhibitor of granular release.

A2
concludes

103790-219666